Article Sidebar
Published:
Jan 13, 2016Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Role of CD5-negative CD8<sup>+</sup> T Cells in Adaptation to Antigenic Variation of Human Immunodeficiency Virus Type 1
Abstract
Purpose: To investigate the effect of 3-oxotirucalla-7, 24-dien-21-oic acid on CD8+ T cell recovery in human immunodeficiency virus type 1 (HIV-1) disease.
Methods: The increase in the rates of CD8+ T cells over 48 weeks following treatment with 3- oxotirucalla-7, 24-dien-21-oic acid was investigated. Plasma HIV-1 load was measured by Versant™ HIV-1 RNA 3.0 branched chain DNA assay while flow cytometry was used for blood CD4 cell counts. For the analysis of the data obtained, Stata version 9.0 was employed.
Results: 3-Oxotirucalla-7, 24-dien-21-oic acid treatment increased CD8+ T cell count from a median of 89 % at baseline to 99 % at 48 weeks. The proportion of patients with CD8+ T cell count < 90 % decreased from 50 % at baseline to 1 %. There was a similar rate of phase 1 CD8+ T cell recovery and greater rates of phase 2 recovery in patients with baseline CD8+ T counts < 50 cells/μL. Among those that achieved CD8+ T cell count > 500 cells/μL at 48 weeks, 23 % had baseline CD8+ T cell counts of < 50 cells/μL. However, the proportion of the patients that attained CD8+ T count of 200 cells/μL at 48 weeks was lower than those with higher baseline CD4 cell counts.
Conclusion: 3-Oxotirucalla-7,24-dien-21-oic acid treatment induces greater tendency for CD8+ T cell recovery in patients with baseline CD8+ T cell counts < 50 cells/μL during 48 weeks of treatment. Therefore, 3-oxotirucalla-7,24-dien-21-oic acid is a promising agent for CD8+ T cell count recovery in patients with HIV infection.
Keywords: CD8+ T cells, HIV infection, Oleanolic acid, Lymphocyte cell, Cell recovery
